<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">568240</article-id><article-id pub-id-type="doi">10.26442/20751753.2023.4.202301</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Subacute thyroiditis: clinical significance of diffuse 18-fluorodeoxyglucose uptake. Case report</article-title><trans-title-group xml:lang="ru"><trans-title>Подострый тиреоидит: клиническое значение диффузной фиксации 18-фтордезоксиглюкозы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4045-1247</contrib-id><name-alternatives><name xml:lang="en"><surname>Ognerubov</surname><given-names>Nikolai A.</given-names></name><name xml:lang="ru"><surname>Огнерубов</surname><given-names>Николай Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Cand. Sci. (Law), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, канд. юрид. наук, проф., зав. каф. онкологии Медицинского института, засл. работник высшей школы РФ, засл. врач РФ</p></bio><email>ognerubov_n.a@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4165-8397</contrib-id><name-alternatives><name xml:lang="en"><surname>Antipova</surname><given-names>Tatiana S.</given-names></name><name xml:lang="ru"><surname>Антипова</surname><given-names>Татьяна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>doctor</p></bio><bio xml:lang="ru"><p>врач</p></bio><email>ognerubov_n.a@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Palkina</surname><given-names>Elena E.</given-names></name><name xml:lang="ru"><surname>Палкина</surname><given-names>Елена Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>cytologist</p></bio><bio xml:lang="ru"><p>врач-цитолог</p></bio><email>palkina68@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Derzhavin Tambov State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Тамбовский государственный университет им. Г.Р. Державина»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">PET-Technology</institution></aff><aff><institution xml:lang="ru">ООО «ПЭТ-Технолоджи», Центр ядерной медицины</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Tambov Regional Oncological Clinical Dispensary</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Тамбовский областной онкологический клинический диспансер»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-04-10" publication-format="electronic"><day>10</day><month>04</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><issue-title xml:lang="en">Endocrinology</issue-title><issue-title xml:lang="ru">Эндокринология</issue-title><fpage>274</fpage><lpage>277</lpage><history><date date-type="received" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/568240">https://consilium.orscience.ru/2075-1753/article/view/568240</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>Subacute thyroiditis is a rare inflammatory thyroid disease presumably associated with viral infection, including COVID-19. It accounts for about 5% of all thyroid diseases.</p> <p><bold>Materials and methods. </bold>A clinical case of de Quervain's subacute thyroiditis in a patient with diffuse hypermetabolic 18-fluorodeoxyglucose uptake by the thyroid gland is presented.</p> <p><bold>Results. </bold>A 61-year-old patient with no history of thyroid disorders 3 weeks after COVID-19 experienced fever in the evenings (37.8–39.8°C). He had moderate pain in the thyroid gland with radiation to the jaw, severe weakness, hand tremors, shivers, 12 kg weight loss, and sweating. These symptoms lasted for 3 weeks. Physical examination showed an enlarged thyroid gland, dense and extremely tender, especially its left lobe. Ultrasound showed an enlarged thyroid gland with a heterogeneous structure and large hypoechoic areas in both lobes up to 4×7 mm with fuzzy contour. Color Doppler imaging revealed reduced blood flow. Combined positron-emission and X-ray computed tomography with 18-fluorodeoxyglucose showed an increased diffuse uptake of the radiopharmaceutical in the thyroid gland and enlargement of its lobes, SUVmax 10.55. Blood thyroid-stimulating hormone is low, free triiodothyronine and thyroxine are high, and ferritin concentration is markedly increased, consistent with thyrotoxicosis. A fine-needle aspiration biopsy was performed. Cytology confirmed de Quervain's subacute thyroiditis. Glucocorticoids and nonsteroidal anti-inflammatory drugs were administered. Four weeks after the treatment, the clinical manifestations resolved. The patient was assessed in 6 months. Ultrasound showed a thyroid gland of regular size with smooth contours; color Doppler mapping revealed normal blood flow. Thyroid-stimulating hormone, triiodothyronine, and thyroxine were within reference ranges.</p> <p><bold>Conclusion. </bold>The SARS-CoV-2 virus can be regarded as the cause of subacute thyroiditis. Combined positron-emission and X-ray computed tomography with 18-fluorodeoxyglucose showed diffuse intensive radiopharmaceutical uptake in the thyroid gland. Cytology is the basis for differential diagnostics. Glucocorticoids and nonsteroidal anti-inflammatory drugs are the first-choice agents.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Подострый тиреоидит является редким воспалительным заболеванием щитовидной железы. Предполагают, что причиной его развития является вирусная инфекция, включая COVID-19. На его долю приходится около 5% всех клинических заболеваний щитовидной железы.</p> <p><bold>Материалы и методы. </bold>Представлен клинический случай подострого тиреоидита де Кервена у пациента с диффузной гиперметаболической фиксацией 18-фтордезоксиглюкозы щитовидной железой.</p> <p><bold>Результаты. </bold>Под наблюдением находился пациент 61 года без патологии щитовидной железы в анамнезе. Через 3 нед после перенесенного COVID-19 стала повышаться температура тела по вечерам от 37,8 до 39,8°С. Появились умеренные боли в щитовидной железе с иррадиацией в нижнюю челюсть, сильная слабость, тремор верхних конечностей, дрожь в теле, отмечены похудение на 12 кг, потливость. Продолжительность симптомов – в течение 3 нед. При пальпации щитовидная железа увеличена, плотная, резко болезненная, особенно левая доля. По данным ультразвукового исследования железа увеличена в размерах, структура ее неоднородная с обширными гипоэхогенными участками в обеих долях размером до 4×7 мм без четких контуров. Цветовое допплеровское картирование – кровоток снижен. Комбинированная позитронно- эмиссионная и рентгеновская компьютерная томография с 18-фтордезоксиглюкозой выявила повышенную диффузную фиксацию радиофармпрепарата в щитовидной железе на фоне увеличения ее долей, SUVmax 10,55. В крови уровень тиреотропного гормона снижен, а свободного трийодтиронина и тироксина – повышен, концентрация ферритина резко увеличена – явления тиреотоксикоза. Выполнена тонкоигольная аспирационная биопсия. При цитологическом исследовании установлен подострый тиреоидит де Кервена. Назначены глюкокортикоиды и нестероидные противовоспалительные препараты. Через 4 нед после лечения клинические проявления регрессировали. Обследован через 6 мес. Согласно ультразвуковому исследованию щитовидная железа не увеличена, контуры ровные, при цветовом допплеровском картировании – обычный характер кровотока. Показатели тиреотропного гормона, трийодтиронина, тироксина – в пределах нормы.</p> <p><bold>Заключение. </bold>Вирус SARS-CoV-2 можно расценивать как причину развития подострого тиреоидита. По данным комбинированной позитронно-эмиссионной и рентгеновской компьютерной томографии с 18-фтордезоксиглюкозой наблюдалось диффузное интенсивное накопление радиофармпрепарата в щитовидной железе. Цитологическое исследование является основой при проведении дифдиагностики. Глюкокортикоиды и нестероидные противовоспалительные препараты составляют базисную терапию.</p></trans-abstract><kwd-group xml:lang="en"><kwd>de Quervain's subacute thyroiditis</kwd><kwd>combined positron emission and X-ray computed tomography with 18-fluorodeoxyglucose</kwd><kwd>diffuse radiopharmaceutical uptake</kwd><kwd>glucocorticoids</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>подострый тиреоидит де Кервена</kwd><kwd>комбинированная позитронно-эмиссионная и рентгеновская компьютерная томография с 18-фтордезоксиглюкозой</kwd><kwd>диффузная фиксация радиофармпрепарата</kwd><kwd>глюкокортикоиды</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Braga M, Brito JP, Lewiński A, Płaczkiewicz-Jankowska E. Subacute Painful Thyroiditis (de Quervain Thyroiditis). McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. Available at: https://empendium.com/mcmtextbook/chapter/B31.II.9.3.3. Accessed: 02.07.2023.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Xu C, Jiang R, Liu JY. Emerging trends and hot spots in subacute thyroiditis research from 2001 to 2022: A bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1144465. DOI:10.3389/fendo.2023.1144465</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sözen M, Topaloğlu Ö, Çetinarslan B, et al. COVID-19 mRNA vaccine may trigger subacute thyroiditis. Hum Vaccin Immunother. 2021;17(12):5120-5. DOI:10.1080/21645515.2021.2013083</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Stasiak M, Michalak R, Stasiak B, Lewinski A. Clinical characteristics of subacute thyroiditis is different than it used to be – current state based on 15 years own material. Neuro Endocrinol Lett. 2019;39(7):489-95.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ramineni P, Kamath SP, Joshi J, Rao S. Subacute thyroiditis with airway compromise in a 5-year-old boy. BMJ Case Rep. 2020;13(11):e236909. DOI:10.1136/bcr-2020-236909</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bostan H, Sencar ME, Calapkulu M, et al. Impact of the COVID-19 pandemic on the incidence, seasonal distribution, and characteristics of subacute thyroiditis. Endocrine. 2022;79(2):323-30. DOI:10.1007/s12020-022-03197-3</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ahn HY, Choi HS, Ha S, Cho SW. Incidence of subacute thyroiditis during the COVID-19 pandemic in south Korea using the national health insurance service database. Thyroid. 2022;32(11):1299-306. DOI:10.1089/thy.2022.0363</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fatourechi V, Aniszewski JP, Fatourechi GZ, et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88:2100-5.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hennessey Jv. Subacute Thyroiditis. [Updated 2018 Jun 12]. In: Endotext. Eds. KR Feingold, B Anawalt, MR Blackman, et al. South Dartmouth (MA): MDText.com, Inc.; 2000. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279084/ Accessed: 12.02.2023.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Yeo SH, Lee SK, Hwang I, Ahn EJ. Subacute thyroiditis presenting as a focal lesion on [18F] fluorodeoxyglucose whole-body positron-emission tomography/CT. Am J Neuroradiol. 2011;32(4):E58-60. DOI:10.3174/ajnr.A2017</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med. 2007;48(6):896-901. DOI:10.2967/jnumed.106.039024</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Quervain F. Über acute, nichteitrige thyroiditis. Arch Für Klin Chir. 1902;67:706-14.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Mangaraj S. Subacute thyroiditis complicating dengue fever – case report and brief review of literature. Trop Doct. 2021;51(2):254-6. DOI:10.1177/0049475520977821</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Zornitzki T, Mildiner S, Schiller T, et al. Subacute thyroiditis-still a diagnostic challenge: Data from an observational study. Int J Environ Res Public Health. 2022;19(15):9388. DOI:10.3390/ijerph19159388</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Volpe The management of subacute (DeQuervain's) thyroiditis. Thyroid. 1993;3(3):253-5.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Xu C, Jiang R, Liu JY. Emerging trends and hot spots in subacute thyroiditis research from 2001 to 2022: A bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1144465. DOI:10.3389/fendo.2023.1144465</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kong M, La Porte S. Case Report: De Quervain's Thyroiditis as a Long-Term Sequelae Complication to SARS-CoV-2 Infection. Case Rep Acute Med. 2021;4(2):64-70. DOI:10.1159/000517705</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after SARS-COV-2 infection. J Clin Endocrinol Metab. 2020;105(7):dgaa276. DOI:10.1210/clinem/dgaa276</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pipitone G, Rindi LV, Petrosillo N, et al. Vaccine-Induced Subacute Thyroiditis (De Quervain's) after mRNA Vaccine against SARS-CoV-2: A Case Report and Systematic Review. Infect Dis Rep. 2022;14(1):142-54. DOI:10.3390/idr14010018</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646-55. DOI:10.1056/NEJMra021194</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Park JY, Choi W, Hong AR, et al. Early thyroid volume reduction in subacute thyroiditis can be a potential indicator for hypothyroidism. Front Endocrinol (Lausanne). 2022;13:888018. DOI:10.3389/fendo.2022.888018</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Stasiak M, Michalak R, Stasiak B, Lewiński A. Time-lag between symptom onset and diagnosis of subacute thyroiditis – how to avoid the delay of diagnosis and unnecessary overuse of antibiotics. Horm Metab Res. 2020;52(1):32-8. DOI:10.1055/a-1033-7524</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Park SY, Kim EK, Kim MJ, et al. Ultrasonographic characteristics of subacute granulomatous thyroiditis. Korean J Radiol. 2006;7:229-34.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Saydam BO, Adiyaman SC, Demir T, et al. The use of low dose prednisolone in patients with subacute thyroiditis and its effect on impaired life and sleep quality. Acta Endocrinol (Buchar). 2022;18(1):64-73. DOI:10.4183/aeb.2022.64</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Arao T, Okada Y, Torimoto K, et al. Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis. J UOEH. 2015;37:103-10.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Iitaka M, Momotani N, Ishii J, et al. Incidence of subacute thyroiditis recurrences after a prolonged latency: 24-year survey. J Clin Endocrinol Metab. 1996;81:466-9.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Huo J, Chen C, Gao D, et al. Ultrasound-guided capsular thyroid injection therapy with dexamethasone and lidocaine mixture for subacute thyroiditis: A single-center study. J Ultrasound Med. 2022;42(3):613-21. DOI:10.1002/jum.16054</mixed-citation></ref></ref-list></back></article>
